Showing 2671-2680 of 4110 results for "".
- Takeda Completes Acquisition of Nimbus’ TYK2 Subsidiaryhttps://practicaldermatology.com/news/takeda-completes-acquisition-of-nimbus-tyk2-subsidiary/2461552/Takeda has expanded its psoriasis treatment portfolio after completing its acquisition of Nimbus Lakshmi from Nimbus Therapeutics in a deal worth up to $6 billion. Under the agreement, which was announced on December 13, 2022, Takeda will acquire TAK-279, formerly known at Nim
- New Biomarkers May Help Advance Melanoma Detectionhttps://practicaldermatology.com/news/new-biomarkers-may-help-advance-melanoma-detection/2461539/New biomarkers to improve skin cancer detection and avoid delays in treatment are being developed by researchers at the University of South Australia. “Melanomas exhibit a wide range of sizes, shapes and growth, which can resemble numerous benign and other malignant skin lesions,&
- Evelo Biosciences’ Atopic Dermatitis Candidate Misses Primary Endpoint in Phase 2 Trialhttps://practicaldermatology.com/news/evelo-biosciences-atopic-dermatitis-candidate-misses-primary-endpoint-in-phase-2-trial/2461540/Data from first three cohorts of Evelo Biosciences’ EDP1815 Phase 2 trial show the atopic dermatitis drug candidate did not meet the primary endpoint, the company announced on Wednesday. Evelo stated that there was an unusually high placebo response rate in the first three cohorts of the st
- Merz Aesthetics, NWSL’s North Carolina Courage Expand Partnershiphttps://practicaldermatology.com/news/merz-aesthetics-partners-with-wsls-north-carolina-courage-to-fuel-confidence-on-and-off-field/2461532/Merz Aesthetics is expanding its sponsorship of the North Carolina Courage, two-time champions of the National Women’s Soccer League (NWSL). “This partnership is so meaningful for us at Merz Aesthetics,” says Patrick Urban, North America President, in
- In Phase 2b Trial, Spesolimab Meets Endpoints for Prevention of Generalized Pustular Psoriasis (GPP) Flareshttps://practicaldermatology.com/news/in-phase-2b-trial-spesolimab-meets-endpoints-for-prevention-of-generalized-pustular-psoriasis-gpp-flares/2461529/Spesolimab (Boehringer Ingelheim), an anti-interleukin-36 receptor antibody, met its primary and key secondary endpoint, demonstrating it can prevent flares in patients with generalized pustular psoriasis (GPP) and provide sustained symptom management up to 48 weeks, according to results of the P
- Phase 2 Data: Jeuveau “Extra-Strength” Dose Produces Lasting Resultshttps://practicaldermatology.com/news/phase-2-data-jeuveau-extra-strength-dose-produces-lasting-results/2461528/Evolus' Jeuveau Extra-Strength achieved one-point improvement on the Glabellar Lines Scale with the duration of effect lasting 26 weeks, representing a prolonged 6-month performance, the Company reports. The extra-strength glabellar line study is a multicenter, double
- Study: 3D-printed Artificial Skin Can Be Used in Cosmetics and Drug Testinghttps://practicaldermatology.com/news/study-3d-printed-artificial-skin-can-be-used-in-cosmetics-and-drug-testing/2461525/Bioprinted artificial skin can be used in cosmetics and drug testing, a new study shows. For the study, researchers compared the conventional mimetic model based on manual pipetting with extrusion bioprinting, which “allows the in vitro reconstruction of a more relevant and repres
- Meet FACE by Galdermahttps://practicaldermatology.com/news/meet-face-by-galderma/2461524/Galderma is launching FACE by Galderma, an app that simulates the results of injectable treatments in real time using digital facial assessment. The technology was unveiled at the International Master Course on Aging Science (IMCAS) World Congress 2023 in Paris. FACE by Galder
- Elsevier Introduces First 3D Human Anatomy Model in Different Skin Toneshttps://practicaldermatology.com/news/elsevier-introduces-first-3d-human-anatomy-model-in-different-skin-tones/2461516/Elsevier is rolling out the newest edition of its 3D anatomy teaching platform, Complete Anatomy 2023, which will feature the most expansive set of skin tone selections ever available in global health education.
- Phase 2b Study: Arcutis' Roflumilast Cream Shows Sustained Efficacy in Adults with Chronic Plaque Psoriasishttps://practicaldermatology.com/news/pgase-2b-study-arcutis-roflumilast-cream-shows-sustained-efficacy-in-adults-with-chronic-plaque-psoriasis/2461513/Arcutis' roflumilast cream showed sustained efficacy with clearance for median of 10 Months in adults with chronic plaque psoriasis, according to an open label Phase 2 long-term safety study presented at the Winter Clinical dermatology meeting. Roflumilast cream